Research Interests:
Our laboratory's research seeks to understand and treat tics and compulsions in Tourette's syndrome (TS), obsessive-compulsive disorder (OCD) and trichotillomania (TTM).
We created the transgenic "Ticcy" mouse, the first animal model of comorbid TS+OCD and TTM. We're now characterizing the dependent biochemical measures (neurotransmitter, receptor and intracellular changes) associated with tics and compulsions, and how they change after drug-alleviation of symptoms and between models of compulsion vs. attention-deficit.
Because the "Ticcy" mice are a drug response-predictive model suitable for rapid-throughput screening of prospective new drugs, Dr. Burton has also gone part-time to start up Psyncretis, Inc., to develop such drugs for these and other disorders comprising biochemically-related small (orphan)-to-large "nested" markets.
Our academic-"U" lab and spin-off company are now both physically sited in a combined academic+private biotech incubator affiliated with Minneapolis Medical Research Foundation (MMRF) and Hennepin County Medical Center (HCMC), next to the Metrodome and Minneapolis' new biotech-biomed incubator, the Elliot Park Lifesciences Institute (EPLI). The company will seek to translate our basic research to the clinic with its Midwest-to-West Coast network of clinical colleagues.
Most Cited Publications:
(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)
Nordstrom, E.J. and Burton, F.H. (2002). A
transgenic model of comorbid Tourette's syndrome and obsessive-compulsive
disorder circuitry. Mol Psychiatry 7, 617-625.
Campbell, M.J., Veldman, M.B., McGrath M.J. and Burton, F.H. (2000).
TS+OCD-like neuropotentiated mice are supersensitive
to seizure induction. NeuroReport, 11, 2335-2338.
McGrath, M.J., Campbell, K.M., Parks, C.R. III and Burton, F.H. (2000). Glutamatergic drugs exacerbate symptomatic behavior
in a transgenic model of comorbid Tourette's Syndrome and obsessive-compulsive
disorder. Brain Res., 877, 23-30.
|